MarketPulse

public offering

49 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics Raises $350M via Public Offering to Fuel Biotech Pipeline

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.
APGEclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Univest Securities, Llc

Univest Closes $16M Offering for Wire Harness Maker Linkers Industries

Univest Securities closed a $16 million public offering for wire harness maker Linkers Industries, raising capital for acquisitions and operations.
LNKSwarrantspublic offering
BenzingaBenzinga··Globe Newswire

EV Maker LOBO Prices $2M Public Offering to Fund Development

LOBO Technologies prices $2M public offering of 3.9M units at $0.51 each, with proceeds for EV development and working capital.
LOBOwarrantspublic offering
BenzingaBenzinga··Not Specified

Outlook Therapeutics Launches Capital Raise Through Public Stock Offering

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.
OTLKwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Reviva Pharmaceuticals Closes $10M Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.
RVPHwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.
RVPHwarrantspublic offering
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SAB Biotherapeutics Raises $85M to Accelerate Diabetes Drug Development

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.
SABSSABSWclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Cytomx Therapeutics, Inc.

CytomX Raises $250M via Stock Offering to Fund Varseta-M Development

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.
AMGNBMYCELGrREGNMRNA+1colorectal cancerpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Olema Oncology Advances Breast Cancer Pipeline, Secures $218.5M in Funding

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.
PFEOLMAPhase 3 trialsclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus Therapeutics Raises $625M in Upsized IPO Offering to Fund Pipeline Expansion

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.
DNTHbiotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Xenon Pharma Raises $650M in Upsized Offering to Fund Pipeline Growth

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.
XENEpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kosmos Energy Raises $185M Via Stock Offering to Reduce Debt Load

Kosmos Energy prices 97.5M share offering at $1.90/share for $185.25M gross proceeds, planning debt repayment.
KOSdebt repaymentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Raises $6M in Public Offering, Exercises Full Warrant Overallotment

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.
CLDIwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Realloys Inc.

REalloys Prices $50M Stock Offering to Fund Operations

REalloys Inc. ($ALOY) prices upsized $50M public offering at $18.50/share, with proceeds designated for working capital and general corporate purposes.
ALOYpublic offeringcapital raising
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Calidi Biotherapeutics Launches Public Offering to Bolster Growth

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.
CLDIwarrantspublic offering
BenzingaBenzinga··Globe Newswire

REalloys Eyes Capital Raise Via Stock Offering Amid Rare Earth Push

REalloys announces underwritten public stock offering with Clear Street, Needham & Company as lead managers to fund operations and general corporate needs.
ALOYworking capitalpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M in Public Offering to Fund Clinical Trials

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.
MAIApublic offeringcommon stock